Investor Overview

Corporate Profile

AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of Afib.

Stock Quote

ATRC (Common)
PriceChange% ChangeVolume
$14.46 - 0.664.37%649,600
Previous CloseToday's OpenIntraday HighIntraday Low
$15.12$14.34$14.82$14.16
Exchange: NASDAQ (US Dollar)
06/24/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Reports

Date
05/06/16
Download Documentation Investor Presentation
04/28/16
Download Documentation  Q1 2016 Earnings Call Transcript
04/18/16
Download Documentation 2015 Annual Report
03/24/15
Download Documentation AtriCure Analyst Day Presentation

All Recent News

DateTitle 
06/21/16AtriCure Announces the First Patient Enrolled in the FROST Cryoanalgesia Study
FROST will evaluate cryoablation of peripheral nerves for the temporary management of post-operative pain MASON, Ohio--(BUSINESS WIRE)--Jun. 21, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient has been enrolled in the FROST study at William Beaumont Hospital, Dearborn, MI. This company-sponsored trial ... 
Printer Friendly Version
05/02/16AtriCure to Present at the UBS Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--May 2, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the UBS Global Healthcare Conference at the Grand Hyatt in New York on Monday, May 23, 2016. Management is scheduled to present at 11:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors p... 
Printer Friendly Version
04/28/16AtriCure Reports First Quarter 2016 Financial Results
Revenue of $35.9 million – up 20.3% as reported, 20.4% constant currency U.S. sales of $28.3 million – up 23.3% International sales of $7.7 million – up 10.1% as reported, 10.9% constant currency MASON, Ohio--(BUSINESS WIRE)--Apr. 28, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced ... 
Printer Friendly Version
04/28/16AtriCure Announces $25 Million Term Loan with Silicon Valley Bank
MASON, Ohio--(BUSINESS WIRE)--Apr. 28, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has entered into an amended and restated term loan and revolving line of credit agreement with Silicon Valley Bank, providing access to a new $25 million five-year term loan, as well as renewing a $15 million revolving line of credit. "We ... 
Printer Friendly Version
  More News >>

National Recent News

DateTitle 
06/21/16AtriCure Announces the First Patient Enrolled in the FROST Cryoanalgesia Study
FROST will evaluate cryoablation of peripheral nerves for the temporary management of post-operative pain MASON, Ohio--(BUSINESS WIRE)--Jun. 21, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient has been enrolled in the FROST study at William Beaumont Hospital, Dearborn, MI. This company-sponsored trial ... 
Printer Friendly Version
05/02/16AtriCure to Present at the UBS Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--May 2, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the UBS Global Healthcare Conference at the Grand Hyatt in New York on Monday, May 23, 2016. Management is scheduled to present at 11:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors p... 
Printer Friendly Version
04/28/16AtriCure Reports First Quarter 2016 Financial Results
Revenue of $35.9 million – up 20.3% as reported, 20.4% constant currency U.S. sales of $28.3 million – up 23.3% International sales of $7.7 million – up 10.1% as reported, 10.9% constant currency MASON, Ohio--(BUSINESS WIRE)--Apr. 28, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced ... 
Printer Friendly Version
04/28/16AtriCure Announces $25 Million Term Loan with Silicon Valley Bank
MASON, Ohio--(BUSINESS WIRE)--Apr. 28, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has entered into an amended and restated term loan and revolving line of credit agreement with Silicon Valley Bank, providing access to a new $25 million five-year term loan, as well as renewing a $15 million revolving line of credit. "We ... 
Printer Friendly Version
  More National News >>

International Recent News

DateTitle 
01/19/16AtriCure Announces Approval for the AtriClip in Japan
Approval opens up a new market for the most widely implanted left atrial appendage occlusion device in the world WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 19, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its AtriClip™ product... 
Printer Friendly Version
10/01/13In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe
AMSTERDAM, Netherlands--(BUSINESS WIRE)--Oct. 1, 2013-- AtriCure, Inc. (Nasdaq: ATRC), is partnering with leading atrial fibrillation (Afib) centers and thought leaders across Europe to provide best-in-class training on surgical ablation. The launch of an international Maze IV Training program will take place on October 1 in Germany at Sana Stuttgart Cardiac Surgery Center, one of six initial European hospitals selected to participate in th... 
Printer Friendly Version
06/18/13Promising Mid-Term Results From Thoracoscopic Ablation of Persistent Atrial Fibrillation Presented at Meeting of International Society for Minimally Invasive Cardiothoracic Surgery
Patients show three-year freedom from atrial fibrillation, anti-arrhythmic drugs PRAGUE--(BUSINESS WIRE)--Jun. 18, 2013-- A leading German cardiovascular heart center reported promising mid-term results for the surgical treatment of persistent atrial fibrillation (Afib) during last week’s International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) meeting being held in Prague, Czech Republic. At three-year follow-up, 80 percen... 
Printer Friendly Version
  More International News >>

Company Calendar

There are currently no events scheduled.
  More Events >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.